This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John Meyerhoff, MD
The John Hopkins University School of Medicine Baltimore, Md

Edward H. Livingston, MD
UCLA School of Medicine Los Angeles, Calif

JAMA. 1995;274(8):608.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—A colleague of mine approached me rather concerned because his most recent PSA level was 3.8 ng/mL. According to Dr Gann and colleagues,¹ his risk for developing prostate carcinoma is eightfold greater than if his PSA level had been less than 1.0 ng/mL. His question was this: What do I do now?

It is not intuitively obvious that the risk of developing prostate cancer is increased eightfold if the PSA level is between 3 and 4 ng/mL because, in the study by Gann et al, 37 (10.1%) of 366 patients with prostate cancer had a PSA level between 3 and 4 ng/mL, yet 29 (7.9%) of the 366 cancer patients had PSA levels of less than 1.0 ng/mL. One way to gain perspective on this discrepancy is to track what happens to a group of patients receiving screening. Using the proportions found in the study by . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?